

This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Gastrointestinal disease				
Gastrointestinal disease	Ceramide	<p>A study in mice identified an anticeramide antibody called 2A2 that could help prevent or reduce radiation-induced gastrointestinal syndrome. In mice, the mAb decreased radiation-induced endothelial apoptosis in the intestine and increased survival compared with antibody control.</p> <p>PxRadia Inc.'s 2A2 is in preclinical development for protecting against and mitigating the effects of radiation.</p> <p><i>SciBX</i> 5(17); doi:10.1038/scibx.2012.441 Published online April 26, 2012</p>	Work covered by patent and filed patent applications; licensed to PxRadia	<p>Rotolo, J. <i>et al. J. Clin. Invest.</i>; published online April 2, 2012; doi:10.1172/JCI59920</p> <p>Contact: Richard Kolesnick, Memorial Sloan-Kettering Cancer Center, New York, N.Y. e-mail: r-kolesnick@ski.mskcc.org</p>